. 2016 Feb 29;5(6):1328–1340. doi: 10.1002/cam4.678

Table 5.

HR (95% CI) of each endpoint with BMI by Stage I or I + II overall and by menopausal status

	Cases	Events	All‐cause death			Events	Recurrence			Events	Breast cancer–specific death
			HR	95% CI	P		HR	95% CI	P		HR	95% CI	P
Stage I
All
≥30	266	17	2.85	1.66–4.92	0.0002	17	1.69	1.02–2.81	0.041	7	3.38	1.46–7.83	0.0045
≥25–<30	1473	52	1.30	0.89–1.89	0.18	76	1.14	0.86–1.51	0.38	20	1.42	0.79–2.55	0.24
≥21.8–<25	2765	79	1.17	0.83–1.64	0.37	140	1.10	0.87–1.39	0.43	33	1.32	0.79–2.20	0.29
≥18.5–<21.8	3075	62	1.00 (Reference)^a			155	1.00 (Reference)^a			28	1.00 (Reference)^a
<18.5	725	27	1.90	1.21–2.99	0.0056	46	1.31	0.94–1.82	0.11	8	1.36	0.62–3.00	0.44
P _trend					0.0026				0.081				0.017
Premenopausal
≥30	59	1	3.69	0.46–29.63	0.22	0	–	–	–	0	–	–	–
≥25–<30	276	6	2.46	0.89–6.76	0.082	16	1.54	0.89–2.68	0.13	4	2.60	0.75–9.04	0.13
≥21.8–<25	765	13	2.25	0.99–5.07	0.052	38	1.25	0.83 –1.86	0.29	10	2.85	1.07–7.60	0.037
≥18.5–<21.8	1407	11	1.00 (Reference)^b			67	1.00 (Reference)^b			7	1.00 (Reference)^b
<18.5	344	2	0.75	0.17–3.43	0.71	19	1.10	0.66–1.83	0.73	1	0.56	0.07–4.60	0.59
P _trend					0.034				0.51				0.12
Postmenopausal
≥30	198	14	2.43	1.33–4.44	0.0038	16	2.16	1.26–3.72	0.0052	6	3.12	1.23–7.91	0.017
≥25–<30	1145	45	1.15	0.77–1.74	0.5	57	1.04	0.74 –1.46	0.82	15	1.15	0.58–2.27	0.7
≥21.8–<25	1906	64	1.03	0.70–1.50	0.89	96	1.05	0.78 –1.42	0.74	22	1.03	0.55–1.93	0.92
≥18.5–<21.8	1571	49	1.00 (Reference)^b			84	1.00 (Reference)^b			19	1.00 (Reference)^b
<18.5	354	22	1.85	1.11–3.07	0.018	23	1.29	0.81 –2.04	0.29	5	1.29	0.48–3.48	0.61
P _trend					0.041				0.11				0.14
Stage I + II
All
≥30	781	63	1.69	1.29–2.23	0.0002	85	1.27	1.01–1.60	0.039	39	1.83	1.29–2.60	0.0007
≥25–<30	3575	194	1.04	0.87–1.25	0.67	332	1.03	0.90–1.18	0.69	110	1.07	0.84–1.37	0.56
≥21.8–<25	6141	340	1.10	0.94–1.29	0.23	622	1.10	0.98–1.24	0.092	213	1.20	0.98–1.46	0.079
≥18.5–<21.8	6261	283	1.00 (Reference)^a			596	1.00 (Reference)^a			181	1.00 (Reference)^a
<18.5	1387	87	1.41	1.11–1.80	0.0049	138	1.10	0.91–1.32	0.34	39	1.08	0.76–1.52	0.68
P _trend					0.014				0.11				0.014
Premenopausal
≥30	190	10	1.71	0.88–3.30	0.11	20	1.17	0.74–1.84	0.51	9	1.79	0.89–3.60	0.1
≥25– <30	766	37	1.47	1.00–2.17	0.05	81	1.15	0.89–1.47	0.28	32	1.51	1.00–2.30	0.052
≥21.8–<25	1735	61	1.11	0.80–1.54	0.53	166	1.04	0.86–1.26	0.7	50	1.09	0.76–1.56	0.65
≥18.5–<21.8	2844	89	1.00 (Reference)^b			276	1.00 (Reference)^b			76	1.00 (Reference)^b
<18.5	643	19	0.97	0.59–1.59	0.9	54	0.83	0.62–1.11	0.2	11	0.65	0.35–1.23	0.19
P _trend					0.025				0.23				0.025
Postmenopausal
≥30	558	51	1.66	1.22–2.27	0.0014	63	1.37	1.04–1.80	0.024	29	1.90	1.25–2.88	0.0026
≥25–<30	2677	153	0.96	0.77–1.19	0.7	238	1.00	0.84–1.19	0.99	75	0.98	0.72–1.32	0.88
≥21.8–<25	4172	260	1.07	0.89–1.29	0.48	421	1.12	0.97–1.30	0.13	153	1.26	0.98–1.63	0.073
≥18.5–<21.8	3191	186	1.00 (Reference)^b			306	1.00 (Reference)^b			98	1.00 (Reference)^b
<18.5	697	62	1.44	1.08–1.93	0.013	79	1.26	0.98–1.62	0.067	26	1.33	0.86–2.05	0.2
P _trend					0.14				0.23				0.13

HR, hazard ratio; CI, confidence interval; BMI, body mass index.

Adjusted by age, living place, detection method, family history of breast cancer, radiation therapy, chemotherapy, endocrine therapy, tumor subtypes, menopausal status, and registered year.

Adjusted by age, living place, detection method, family history of breast cancer, radiation therapy, chemotherapy, endocrine therapy, tumor subtypes, and registered year.